Affordable Access

Publisher Website

Clinical response of patients with galactorrhea to pergolide, a potent, long-acting dopaminergic ergot derivative

Authors
Journal
Life Sciences
0024-3205
Publisher
Elsevier
Publication Date
Volume
28
Issue
1
Identifiers
DOI: 10.1016/0024-3205(81)90371-4
Disciplines
  • Medicine

Abstract

Abstract Pergolide is an ergot derivative with dopaminergic activity and, like bromocriptine, can suppress prolactin release from the pituitary gland. In a single blind study pergolide was administered for 90 days to three females with idiopathic hyperprolactinemia manifested by galactorrhea and amenorrhea. Response to therapy was followed clinically and by determination of plasma prolactin concentrations. Pergolide lowered plasma prolactin concentrations and suppressed galactorrhea in all patients. Menstruation recurred in both patients with intact GU systems. Side effects were minor and tolerance developed to all but nasal stuffiness. Pergolide appears to be efficacious therapy for patients with amenorrhea/galactorrhea secondary to hyperprolactinemia.

There are no comments yet on this publication. Be the first to share your thoughts.